Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary

Takeshi Hisamatsu1, Seiji Mabuchi1, Yuri Matsumoto1, Mahiru Kawano1, Tomoyuki Sasano1, Ryoko Takahashi1, Kenjiro Sawada1, Kimihiko Itō2, Hirohisa Kurachi3, Russell J. Schilder4, Joseph R. Testa5, and Tadashi Kimura1

Abstract

The goal of this study was to examine the role of mTOR complex 2 (mTORC2) as a therapeutic target in ovarian clear cell carcinoma (CCC), which is regarded as an aggressive, chemoresistant histologic subtype. Using tissue microarrays of 98 primary ovarian cancers [52 CCCs and 46 serous adenocarcinomas (SACs)], activation of mTORC2 was assessed by immunohistochemistry. Then, the growth-inhibitory effect of mTORC2-targeting therapy, as well as the role of mTORC2 signaling as a mechanism for acquired resistance to the mTOR complex 1 (mTORC1) inhibitor RAD001 in ovarian CCC, were examined using two pairs of RAD001-sensitive parental (RMG2 and HAC2) and RAD001-resistant CCC cell lines (RMG2-RR and HAC2-RR). mTORC2 was more frequently activated in CCCs than in SACs (71.2% vs. 45.7%). Simultaneous inhibition of mTORC1 and mTORC2 by AZD8055 markedly inhibited the proliferation of both RAD001-sensitive and -resistant cells in vitro. Treatment with RAD001 induced mTORC2-mediated AKT activation in RAD001-sensitive CCC cells. Moreover, increased activation of mTORC2-AKT signaling was observed in RAD001-resistant CCC cells compared with the respective parental cells. Inhibition of mTORC2 during RAD001 treatment enhanced the antitumor effect of RAD001 and prevented CCC cells from acquiring resistance to RAD001. In conclusion, mTORC2 is frequently activated, and can be a promising therapeutic target, in ovarian CCCs. Moreover, mTORC2-targeted therapy may be efficacious in a first-line setting as well as for second-line treatment of recurrent disease developing after RAD001-treatment.

Introduction

The mTOR is a serine/threonine kinase that plays a key role in cell growth and proliferation (1). In cells, mTOR resides in at least 2 functionally distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 phosphorylates the translation-regulating factors S6K-1 (ribosomal S6 kinase-1) and 4EBP-1 (eukaryote translation initiation factor 4E-binding protein-1), and regulate a variety of processes including proliferation, motility, differentiation, survival, autophagy, angiogenesis, and metabolism in response to nutrients or growth factor signals (1). The more recently identified mTORC2 phosphorylates the survival kinase AKT, protein kinase Ca, and SGK1, leading to regulation of the actin cytoskeleton network (2).

Frequent mTOR activation in human epithelial ovarian cancer was first described in a 2004 report, in which AKT–mTORC1 signaling was shown to be activated in 55% of epithelial ovarian cancers (3). A subsequent preclinical study specifically targeting ovarian clear cell carcinoma (CCC), a chemoresistant histologic subtype of epithelial ovarian cancer, revealed that mTORC1 is more frequently activated in CCC than in the more common subtype, serous adenocarcinoma (SAC): 86.6% vs. 50%, respectively (4). This finding may be explained by the recent finding that activating mutations of PIK3CA occur more frequently in CCC than in any other histologic subtypes of epithelial ovarian cancer (5), suggesting that patients with CCC may be more responsive to mTORC1-targeted therapy (6, 7). Given that patients with CCC have poor prognosis due mainly to the lack of effective chemotherapy (8, 9), hopes are high for the development of mTOR-targeting therapy in this patient population (10).

Rapamycin and its analogs (rapalogs) are all highly specific inhibitors of mTORC1. The rapalogs inhibit mTORC1 by first binding to the intracellular protein FK506-binding protein 12 (FKBP12). The resulting mTOR...
inhibitor–FKBP12 complex then binds to mTOR at the FKBP12–rapamycin–binding domain (FRB), thereby inhibiting the serine/threonine kinase activity of mTORC1 by an allosteric mechanism (11). Although rapalogs have shown significant growth-inhibitory effects on a variety of human malignancies, it is increasingly recognized that the mechanism of action of rapalogs may not be sufficient for achieving a broad and robust anticancer effect due to their inability to inhibit mTORC2 activity (12). In fact, in a phase III clinical study, patients with renal cell carcinoma treated with everolimus experienced disease progression with a median progression-free interval of only 4 months (13).

In ovarian cancer, although the role of mTORC1 as a therapeutic target has been intensively investigated preclinically (4, 14–17), the mechanism responsible for resistance to mTORC1 inhibitors has not been reported previously. Moreover, with regard to mTORC2, only limited in vitro information is available (18).

In this report, we examine the involvement of mTORC2 activation in both early stage and advanced stage ovarian cancer and its possible role as a therapeutic target. We also evaluate the role of mTORC2 as a mechanism for acquired resistance to the mTORC1 inhibitor RAD001 in CCC cells. Finally, we investigate whether inhibition of mTORC2 activity can prevent CCC cells from acquiring resistance to RAD001.

Materials and Methods
Reagents/antibodies
RAD001 was obtained from Novartis Pharma AG. AZD8055 was purchased from Selleck Chemicals. Enhanced chemiluminescence Western blotting detection reagents were from PerkinElmer. Antibodies recognizing Rictor, phospho-Rictor (Thr1135), S6K1, phospho-S6K1 (Thr389), AKT, phospho-AKT (Ser473), PRAS40, phospho-PRAS40 (Thr246), 4EBP1, phospho-4EBP1 (Thr37/46), and β-actin were obtained from Cell Signaling Technology. Anti-rabbit secondary antibodies were purchased from Santa Cruz Biotechnology. The CellTiter 96-well proliferation assay kit was obtained from Promega.

Cell lines and culture
Human ovarian CCC cell lines RMG1, RMG2, KOC7C, and HAC2 were kindly provided by Dr. H. Itamochi (Tottori University, Tottori, Japan). These cell lines were extensively characterized previously (19–24). We tested these cell lines in our laboratory for its authentication by morphologic observation. No further cell line authentication was conducted by the authors. Each cell line was never continuously passaged in culture for more than 3 months, and after that, a new vial of frozen cells was thawed. These cells were cultured in DMEM:Ham’s F-12, (Gibco) with 10% FBS, as reported previously (4, 14, 24).

Determination of cell number
CCC cells were seeded into 96-well plates at a density of 3 × 10^4/well. The monolayers were washed once with PBS, the cells were detached with trypsin, and viable cells were counted by Trypan blue dye exclusion.

Establishment of RAD001-resistant cell lines
RAD001-resistant sublines from RMG2 and HAC2 were developed by continuous exposure to RAD001 (Supplementary Fig. S1). Briefly, cells of both lines were exposed to stepwise increases in RAD001 concentration. Initial RAD001 exposure was at a concentration of 1 nmol/L. After the cells had regained their exponential growth rate, the RAD001 concentration was doubled and then the procedure was repeated until selection at 1 μmol/L was attained. The resulting RAD001-resistant sublines, designated as RMG2-RR and HAC2-RR, were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 1 μmol/L RAD001 to maintain a high level of RAD001-resistance.

Cell proliferation assay
A MTS assay was used to analyze the effect of RAD001 or AZD8055 on cell viability as described previously (25). Cells were cultured overnight in 96-well plates (1 × 10^4 cells/well). Cell viability was assessed after addition of RAD001 or AZD8055. The number of surviving cells was assessed by determination of the A_{490nm} of the dissolved formazan product after addition of MTS.

Cell-cycle analysis
Cells were incubated with 10 nmol/L RAD001 or 10 nmol/L AZD8055 for 48 hours. Cells were then fixed with 75% ethanol, and stained with propidium iodide (50 μg/mL) in the presence of RNase A (100 μg/mL; Roth) for 20 minutes at 4°C. Cell-cycle distribution was determined by analyzing 10,000 cells using a FACSscan flow cytometer and CellQuest software (Becton Dickinson) as reported elsewhere (15).

In vitro detection of apoptosis
Cells were treated with 10 nmol/L RAD001 or 10 nmol/L AZD8055 for 24 hours in the presence of 5% FBS. In brief, cells were lysed and DNA fragmentation was detected using a Cell Death Detection ELISA Kit (Roche) as per the manufacturer’s instructions.

Western blot analysis
Cells treated as indicated were lysed for 10 minutes at 4°C. Equal amounts of proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Western blot analyses were conducted using various specific primary antibodies. Immunoblots were visualized with horseradish peroxidase–coupled immunoglobulin by using an enhanced chemiluminescence Western blotting system (PerkinElmer).

mTORC2 kinase assays
Kinase assays of endogenous mTORC2 were conducted as described previously (26). The cells were lysed on ice for 10 minutes in 1 mL lysis buffer. After centrifugation, the supernatant was incubated with anti-Rictor antibody.
at 4°C for 12 hours, followed by incubation with protein A-agarose for another 2 hours. Immunocomplexes were incubated in kinase reaction buffer containing 50 ng of inactive AKT and 50 μmol/L ATP for 30 minutes at 37°C. The reaction was terminated by adding 6× SDS sample buffer, and AKT phosphorylation was detected by Western blotting.

RNA interference

The siRNA specifically targeting S6K1 (catalog #sc-36165) and a nontargeting control siRNA (catalog #sc-37007) were purchased from Santa Cruz Biotechnology. The short hairpin RNA (shRNA) specifically targeting Rictor (catalog #TG307650) and a nontargeting control shRNA (catalog #TR30013) were purchased from Origene. RMG2 and HAC2 cells incubated in 6-well plates were transfected with siRNA or shRNA using Lipofectamine 2000 (Invitrogen). Transiently transfected cells were assayed 48 hours posttransfection. The shRNA plasmids carried a kanamycin resistance gene that permits the selection of stable transfectants. Clonal selection was conducted by adding kanamycin (Sigma) into the medium approximately 24 hours after transfection. The resulting stable transfectants expressing control shRNA or Rictor shRNA were designated as cell lines RMG2-control, RMG2-RictorKD, HAC2-control, and HAC2-RictorKD.

Clinical samples

All surgical specimens including ovarian cancers and normal ovaries were collected and archived according to protocols approved by the Institutional Review Boards of the parent institutions. Appropriate informed consent was obtained from each patient. The tumors included 46 SACs and 52 CCCs. On the basis of criteria of the Federation Internationale des Gynaecologistes et Obstétristes (FIGO), 22 SACs were stage I–II tumors and 24 were stage III–IV tumors. Among CCCs, 27 were stage I–II and 25 were stage III–IV.

Immunohistochemistry

Tumor samples were fixed in 10% neutral buffered formalin overnight and then embedded in paraffin. Ovarian cancer tissue microarrays consisting of 2 cores from each tumor sample were prepared by the Tumor Bank Facility at Fox Chase Cancer Center (Philadelphia, PA), as described previously (4, 24). Tissue sections were cut at 4 μm, mounted on slides, and processed for immunohistochemical staining. Sections were incubated with the primary antibody, followed by the appropriate peroxidase-conjugated secondary antibody. The slides were scored semiquantitatively by 2 pathologists who were blinded to the clinical outcome. Surrounding non-neoplastic stroma served as an internal negative control for each slide. A score of 0 indicated no staining, +0.5 was weak focal staining (<10% of the cells stained), +1 was indicative of focal staining (10%–50% of the cells stained), +2 indicated clearly positive staining (>50% of the cells stained), and a score of +3 was intensely positive. Tumors with +0.5 or +1 were combined and designated as the weak-staining group. Tumors with staining of +2 or +3 comprised the medium-staining and strong-staining groups, respectively. When the 2 cores from the same tumor sample showed different positivity results, the lower score was considered valid.

In vivo tumor studies

All procedures involving animals and their care were approved by the Institutional Animal Care and Usage Committee of Osaka University (Suita, Osaka, Japan), in accordance with institutional and NIH (Bethesda, MD) guidelines. Five- to 7-week-old nude mice (n = 40) were inoculated subcutaneously into the right flank either with 5 × 106 RMG2-control, RMG2-RictorKD, HAC2-control, or HAC2-RictorKD cells in 200 μL of PBS, with 10 mice in each group. When tumors reached about 50 mm³, the mice were assigned into 2 treatment groups: placebo (n = 5) or 2.5 mg/kg RAD001 (n = 5), with treatment given every 2 days. RAD001 was administered intragastrically using an animal-feeding needle. Caliper measurements of the longest perpendicular tumor diameters were done every week to estimate tumor volume using the following formula: \( V = \frac{L \times W \times D}{2} \), where \( V \) is the volume, \( L \) is the length, \( W \) is the width, and \( D \) is the depth.

Statistical analysis

The effect of mTOR inhibition on cell proliferation and apoptosis was analyzed by Student t test. Tumor volume was analyzed by Wilcoxon exact test. Immunoreactivity was analyzed using Fisher exact test. Spearman correlation coefficient with confidence interval (CI) was calculated to assess the relationship between phospho-mTOR (Ser2481) immunoreactivity and phospho-AKT immunoreactivity.

Results

mTORC2 is expressed and more frequently activated in CCCs than in SACs

Phosphorylation of mTOR at Ser2481 has been reported to be a marker for mTORC2 activation (27, 28). To determine the expression and activation of mTORC2, tissue microarrays and normal ovarian tissues were examined immunohistochemically for phospho-mTOR (Ser2481) and Rictor, an essential component of mTORC2. As shown in Fig. 1A and B and Supplementary Table S1, significantly stronger immunoreactivity for phospho-mTOR (Ser2481) was observed in CCCs and SACs than in ovarian surface epithelial cells. Rictor expression was observed in both ovarian cancers and normal ovarian tissues. Although CCCs with SACs exhibited no differences in immunoreactivity for Rictor, significantly stronger immunoreactivity for phospho-mTOR (Ser2481) was observed in CCCs than in SACs. Among the 46 SACs, 25 (54.3%)
showed negative/weak staining and 21 (45.7%) showed medium staining. No SAC had strong expression of phospho-mTOR (Ser2481). In contrast, among the 52 CCCs, 15 tumors (28.8%) had negative/weak staining, 25 (48.1%) showed medium staining, and 12 (23.1%) stained strongly. The frequency of medium/strong phospho-mTOR immunoreactivity was significantly higher in CCCs than in SACs (71.2% and 45.7%, respectively). When analyzed by clinical stage, as shown in Fig. 1C, medium/strong phospho-mTOR (Ser2481) expression was observed in 76% of advanced stage CCCs and in 66.7% of early stage CCCs, compared with 40.9% and 50.0% in advanced stage and early stage SACs, respectively. Collectively, these results indicate that mTORC2 is frequently expressed and activated in CCCs than in SACs, especially those in advanced stage disease.

mTORC2 is known to phosphorylate AKT at Ser 473, and thus, AKT phosphorylation has also been used as a marker for mTORC2 activation (12). To determine if mTOR phosphorylation at Ser2481 in our CCCs paralleled AKT phosphorylation (Ser473), immunohistochemical analysis was conducted and the immunoreactivity was scored semiquantitatively. In total, 28 of 52 (53.8%) CCCs showed significant expression of both phospho-AKT (Ser473) and phospho-mTOR (Ser2481) and 10 of 52 (19.2%) tumors showed phosphorylation of neither AKT nor mTOR (Table 1). Altogether, an association between phospho-AKT (Ser473) staining and phospho-mTOR (Ser2481) staining was observed in 38 of 52 ovarian tumors and 21 of 28 CCCs, respectively.

Figure 1. mTORC2 is frequently expressed and activated in ovarian CCCs. Ovarian cancer tissue microarrays and normal ovarian tissues were stained with either anti-Rictor or anti-phospho-mTOR (Ser2481) antibodies. A, representative photographs of ovarian tissue microarray cores. Magnifications, ×100 and ×400 (inset). B, histogram indicating immunoreactivity profile. C, histogram indicating immunostaining profile by clinical stage. Proportion indicates proportion of medium/strong-staining tumors. *, P < 0.05. D, mTORC2 activation status in 4 ovarian CCC cell lines. CCC cells were serum-starved overnight, after which the mTORC2 activity was determined by in vitro kinase assay. Briefly, the cell lysates were incubated with anti-Rictor antibody followed by incubation with protein A-agarose. Immunocomplexes were incubated in kinase reaction buffer, and phospho-AKT and Rictor were detected by Western blotting. I.B., immunoblot; I.P., immunoprecipitation; N.S., not significant.
As shown in Fig. 2D, treatment with AZD8055 greatly inhibited the phosphorylation of these molecules. In contrast, although treatment with RAD001 potently inhibited S6K1, it could not inhibit the phosphorylation of 4EBP1 (Thr37/46) and AKT (Ser473). In fact, RAD001 was found to induce phosphorylation of AKT. It has been reported that the greater inhibition of 4EBP1 at T37/46 is associated with a greater inhibition of cap-dependent translation and cellular proliferation (29). Thus, the greater antitumor effect of AZD8055 than RAD001 observed in CCC cells may be explained, at least in part, by the effect of AZD8055 on AKT and 4EBP1. Altogether, these results strongly suggest that mTORC2 is a promising therapeutic target for the management of CCCs.

**mTORC1 inhibition by RAD001 induces activation of the AKT signaling pathway**

To further investigate the role of mTORC2 in CCC cells, we next examined whether or not mTORC2 plays a mechanistic role in the resistance to mTORC1 inhibition. For this purpose, we first examined the effect of RAD001 treatment on AKT, a known mTORC2 substrate. As shown in Fig. 3A, treatment with RAD001 induced a modest increase in the phosphorylation of AKT and proline-rich AKT substrate of 40 kDa (PRAS40). In contrast, S6K1 phosphorylation was completely inhibited in both cell lines in response to RAD001 treatment. PRAS40 is known for its ability to negatively regulate mTORC1 kinase activity (30). Recent investigations suggest that the phosphorylation of PRAS40 by AKT results in the dissociation of PRAS40 from mTORC1 and may relieve an inhibitory constraint on mTORC1 activity (30). Thus, our in vitro data suggest that mTORC1 inhibition by RAD001 triggers a negative feedback mechanism resulting in activation of AKT–PRAS40 signaling, which may attenuate the antitumor effect of RAD001 in CCC cells.

**Induction of AKT–PRAS40 phosphorylation after mTORC1 inhibition requires mTORC2**

It has been previously reported that mTORC2-mediated activation of AKT is involved in the mechanism responsible for resistance to rapamycin in diffuse large B-cell lymphoma (31). However, whether this mechanism is cell type specific or whether these preclinical findings are of clinical relevance is unknown.

To determine the mechanism by which RAD001 induces AKT phosphorylation in CCC cells, we used both a mTOR kinase inhibitor (AZD8055) and shRNA against the mTORC2 component Rictor. As shown in Fig. 2D, treatment with RAD001 for 3 hours induced phosphorylation of AKT. However, such AKT phosphorylation was not observed in response to simultaneous inhibition of mTORC1 and mTORC2 by AZD8055, indicative of the involvement of mTORC2 in mTORC1 inhibition-mediated activation of AKT in CCC cells.

To further examine the role of mTORC2 in RAD001-induced AKT phosphorylation, cells were transiently transfected with shRNA against Rictor before treating...
with RAD001. As shown in Fig. 3B, specific knockdown of Rictor caused a reduction in the basal level of Rictor and in the phosphorylation of AKT and PRAS40. Collectively, these data indicate that AKT phosphorylation following mTORC1 inhibition in CCC cells is mediated in a mTORC2-dependent manner and can be blocked by mTORC2 inhibition.

We further investigated the mechanism by which mTORC2 is activated in response to RAD001 treatment. A recent report showed that S6K1 directly phosphorylates Rictor on Thr1135, negatively regulating the ability of mTORC2 to phosphorylate AKT (32). As shown in Fig. 3A, treatment of CCC cells with RAD001 attenuated the phosphorylation of S6K1 and Rictor (Thr1135) in a time-dependent manner, which sharply contrasts with the increased phosphorylation of AKT seen following RAD001 treatment. Moreover, specific knockdown of S6K1 by siRNA attenuated the phosphorylation of Rictor (Thr1135), which resulted in increased activation of mTORC2 (Fig. 3C). These results imply that RAD001-induced mTORC2 activation occurs by attenuating S6K1-mediated Rictor phosphorylation (Fig. 3D).

**mTORC2–AKT activation is responsible for resistance to RAD001**

To investigate whether mTORC1 inhibition-mediated mTORC2 activation is linked mechanistically to RAD001 resistance, we established RAD001-resistant cell lines from RMG2 and HAC2 cells (Supplementary Fig. S1). We next examined the activity of mTORC2 in both RAD001-resistant sublines and parental RAD001-sensitive cells by in vitro kinase assay. As shown in Fig. 4A, greater activation of mTORC2 was observed in the RAD001-resistant sublines compared with the respective parental cell lines. We also investigated AKT–PRAS40 signaling in both RAD001-resistant sublines and parental cells by Western
blotting. As shown in Fig. 4B, significantly higher phospho-AKT and phospho-PRAS40 expression levels were observed in both RAD001-resistant sublines relative to the respective parental cell lines.

We next investigated whether the hyperphosphorylation of AKT–PRAS40 signaling observed in RAD001-resistant CCC cells is mediated by mTORC2. As shown in Fig. 4C, knockdown of Rictor resulted in attenuated phosphorylation of AKT and PRAS40 in RAD001-resistant CCC cells. Similarly, treatment with AZD8055 inhibited the phosphorylation of both AKT and PRAS40 in RAD001-resistant CCC cells (Fig. 4D). Collectively, our results indicate that the hyperphosphorylation of AKT observed in RAD001-resistant CCC cells is mediated by mTORC2 and that RAD001 resistance is mediated, at least in part, by activation of mTORC2–AKT signaling in CCC cells.

Inhibition of mTORC2 prevents CCC cells from acquiring resistance to RAD001

We next examined whether continuous inhibition of mTORC2 during the course of RAD001 treatment in vivo can prevent CCC cells from acquiring resistance to RAD001. For this purpose, we established cell lines stably expressing Rictor shRNA. As shown in Fig. 5A, CCC cells expressing Rictor shRNA (RMG2-RictorKD cells and HAC2-RictorKD cells) had significantly reduced levels of Rictor compared with control cells. RAD001-mediated feedback activation of AKT. In a normal condition, S6K1 directly phosphorylates Rictor on Thr1135, which negatively regulates the ability of mTORC2 to phosphorylate AKT. mTORC1-inhibition by RAD001 triggers negative feedback mechanisms resulting in mTORC2-mediated phosphorylation of AKT–PRAS40.

![Diagram](https://example.com/diagram.png)
Using these cell lines, we first examined the in vitro growth-inhibitory effect of RAD001. As shown in Fig. 5B, although both RMG2-control cells and HAC2-control cells showed sensitivity to RAD001 treatment at day 3, the cells started to proliferate again thereafter, resulting in an increased number of cells at day 7. In contrast, in RMG2-RictorKD cells and HAC2-RictorKD cells, RAD001 treatment decreased the number of viable CCC cells in a time-dependent manner, resulting in almost 90% disappearance of CCC cells at day 7. We then determined the effect of RAD001 on the in vivo growth of RMG2-RictorKD- and HAC2-RictorKD-derived tumors. As shown in Fig. 5C, in mice treated with placebo, the RMG2-RictorKD-derived tumor was significantly smaller than that of RMG2-control-derived tumor, indicating that knockdown of Rictor inhibits the in vivo growth of CCC cells. When the mice were treated with RAD001, clear differential sensitivity to RAD001 was observed between RMG2-RictorKD-derived tumors and control RMG2-control-derived tumors. Moreover, RAD001 treatment showed long-lasting antitumor effects on tumors derived from RMG2-RictorKD cells. Similar results were observed in mice inoculated with HAC2-RictorKD or HAC2-control cells. Together, these results indicate that inhibition of mTORC2 activity during RAD001 treatment enhances the therapeutic efficacy of RAD001 and prevented CCC cells from acquiring resistance to RAD001.

We finally determined the growth-inhibitory effect of AZD8055 in RAD001-resistant CCC cells. As shown in Fig. 5D, in contrast to the effect of the mTORC1 inhibitor RAD001, simultaneous inhibition of mTORC1 and mTORC2 by treatment with AZD8055 inhibited the proliferation of RAD001-resistant CCC cells. RMG2-RR and HAC2-RR cells were treated with 10 nmol/L AZD8055 for 8 hours. Cells were harvested, lysed, and then equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with various antibodies. IgG, immunoglobulin G; I.B., immunoblot, I.P., immunoprecipitation.

Using these cell lines, we first examined the in vitro growth-inhibitory effect of RAD001. As shown in Fig. 5B, although both RMG2-control cells and HAC2-control cells showed sensitivity to RAD001 treatment at day 3, the cells started to proliferate again thereafter, resulting in an increased number of cells at day 7. In contrast, in RMG2-RictorKD cells and HAC2-RictorKD cells, RAD001 treatment decreased the number of viable CCC cells in a time-dependent manner, resulting in almost 90% disappearance of CCC cells at day 7. We then determined the effect of RAD001 on the in vivo growth of RMG2-RictorKD- and HAC2-RictorKD-derived tumors. As shown in Fig. 5C, in mice treated with placebo, the RMG2-RictorKD-derived tumor was significantly smaller than that of RMG2-control-derived tumor, indicating that knockdown of Rictor inhibits the in vivo growth of CCC cells. When the mice were treated with RAD001, clear differential sensitivity to RAD001 was observed between RMG2-RictorKD-derived tumors and control RMG2-control-derived tumors. Moreover, RAD001 treatment showed long-lasting antitumor effects on tumors derived from RMG2-RictorKD cells. Similar results were observed in mice inoculated with HAC2-RictorKD or HAC2-control cells. Together, these results indicate that inhibition of mTORC2 activity during RAD001 treatment enhances the therapeutic efficacy of RAD001 and prevented CCC cells from acquiring resistance to RAD001.

We finally determined the growth-inhibitory effect of AZD8055 in RAD001-resistant CCC cells. As shown in Fig. 5D, in contrast to the effect of the mTORC1 inhibitor RAD001, simultaneous inhibition of mTORC1 and mTORC2 by treatment with AZD8055 inhibited the proliferation of RAD001-resistant CCC cells in a dose-dependent manner. This finding indicates that simultaneous inhibition of mTORC1 and mTORC2 might be efficacious in patients with CCC who become resistant to RAD001 therapy.

Discussion

CCC of the ovary is a distinctive subtype of epithelial ovarian cancer associated with a poorer sensitivity to
platinum-based chemotherapy and a worse prognosis than more common SACs both in first-line and recurrent settings (8, 9, 33). Therefore, to improve survival of patients with CCC, novel treatment strategies need to be developed.

Previous investigations indicated that mTORC1 is frequently activated in CCC of the ovary and in vitro studies suggested that mTORC1 can be targeted therapeutically (4, 17). On the basis of promising results from preclinical and clinical investigations (4, 17, 34), the Gynecologic Oncology Group (GOG) is currently conducting a phase II trial (protocol GOG0268) designed to evaluate the efficacy of temsirolimus in combination with carboplatin-paclitaxel as a first-line chemotherapy in patients with stage III–IV CCC of the ovary (7). In addition, for patients with recurrent CCC of the ovary, the Japanese Gynecologic Oncology Group (JGOG) will soon initiate a phase II trial of everolimus monotherapy in their protocol JGOG3012.

Compared with mTORC1, the role of mTORC2 as a therapeutic target in CCC of the ovary has not been previously documented. However, there is emerging evidence for a role for mTORC2 as an important driver for tumorigenesis. It has been reported that exogenous overexpression of Rictor promotes mTORC2 activity, increases proliferative and invasive potential of cancer...
AZD8055 is an orally bioavailable mTOR kinase inhibitor that is currently being evaluated in phase I/II clinical studies in a variety of solid tumors. AZD8055 binds to the mTOR kinase domain and directly affects both mTORC1 and mTORC2 kinase activity. Thus, AZD8055 theoretically would be expected to have a more profound effect on mTOR signaling than rapalogs that target only mTORC1 (37). As shown in Fig. 2B and C, treatment with AZD8055 had more robust antitumor activity than RAD001 in RAD001-sensitive CCC cells, with IC50 values in a low nanomolar range. This finding may be explained, at least in part, by reduced mTORC2 activity by knockdown of Rictor during RAD001 treatment prevented RMG1 cells from acquiring resistance to RAD001 (Fig. 5B). Collectively, these results indicate that the Rictor–mTORC2–AKT–PRAS40 feedback loop induced by RAD001 treatment is, at least in part, responsible for acquired resistance to RAD001 (Fig. 3D).

An additional important finding in our study is the potent antitumor activity of AZD8055 in RAD001-resistant CCC (Fig. 5D). Given that patients with renal cell carcinoma treated with everolimus experienced disease progression with a median progression-free interval of 4 months in a phase III study (13), it is of great importance to explore the salvage treatment of recurrent tumors developed after everolimus treatment. Our results suggest that mTOR inhibitors that inhibit both mTORC1 and mTORC2 might be efficacious for the clinical management of recurrent CCCs developed after the treatment with a mTORC1 inhibitor such as RAD001.

In summary, our results indicate that mTORC2 is frequently activated in ovarian CCC and is a promising therapeutic target for this disease both as a first-line treatment and as a salvage treatment for recurrence after everolimus treatment. This work provides scientific rationale for future clinical trials of mTORC2-targeting therapies in patients with ovarian CCC, a chemoresistant histologic subtype characterized by frequent hyperactivation of the mTOR complexes.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: S. Mabuchi, R.J. Schilder
Development of methodology: T. Hisamatsu, S. Mabuchi, K. Sawada
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Hisamatsu, R. Takahashi, K. Ito, J.R. Testa
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Hisamatsu, R. Takahashi
Writing, review, and/or revision of the manuscript: T. Hisamatsu, S. Mabuchi, Y. Matsumoto, M. Kawano, T. Sasano, H. Kurachi, R.J. Schilder, J.R. Testa, T. Kimura
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T. Hisamatsu, S. Mabuchi, T. Kimura
Study supervision: S. Mabuchi

Acknowledgments
The authors thank Drs. Y. Nishio, M. Tsujimoto, M. Ohmichi, Y. Terai, M. Yamoto, and Y. Tsukuba for providing tumor specimens and clinical information.

Grant Support
S. Mabuchi is supported in part by grant-in-aid for General Scientific Research, no. 23590246, from the Ministry of Education, Culture, Sports, Science and Technology of Japan. H. Kurachi is supported in part by grant-in-aid for General Scientific Research, no. 22390308, from the Ministry of Education, Culture, Sports, Science and Technology of Japan. J.R. Testa received support from National Cancer Institute (NCI) grant CA77429.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 11, 2012; revised April 17, 2013; accepted April 17, 2013; published OnlineFirst April 24, 2013.
mTORC2-Targeted Therapy for Ovarian Clear Cell Carcinoma

References

Molecular Cancer Therapeutics

Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary

Takeshi Hisamatsu, Seiji Mabuchi, Yuri Matsumoto, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-1185

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2013/04/24/1535-7163.MCT-12-1185.DC1

Cited articles
This article cites 38 articles, 16 of which you can access for free at:
http://mct.aacrjournals.org/content/12/7/1367.full.html#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
/content/12/7/1367.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.